NASDAQ$INTS
Intensity Therapeutics Inc · Q4 2023 earnings
Q4 2023 earnings · · Investor relations
Briefing
Announced full year 2023 financial results and provided a corporate update.
Intensity Therapeutics reported its full year 2023 financial results, highlighting the advancement of its lead drug candidate, INT230-6, into late-stage clinical programs and a year-end cash position of $14.8 million expected to fund operations through Q1 2025.
- INT230-6 advances into late-stage clinical programs in sarcoma and breast cancer.
- Received Study May Proceed letter from the FDA for Phase 3 protocol in soft tissue sarcoma.
- Year-end cash and investments of $14.8 million expected to fund operations through the end of Q1 ’25.
- Plans to initiate Phase 3 sarcoma study in mid-2024.
Headline financials
Revenue & EPS history
Intensity Therapeutics · Revenue · Quarterly
$282K
Forward guidance
Intensity Therapeutics anticipates initiating a Phase 3 study in metastatic soft tissue sarcoma subtypes and a Phase 2/3 program in presurgical breast cancer in mid-2024.
Tailwinds
- Initiate INVINCIBLE-3 Study in certain metastatic soft tissue sarcoma subtypes.
- The Company plans to enroll 333 patients with an endpoint of overall survival.
- The study will compare INT230-6 as a monotherapy treatment to the three current SOC drugs in 2nd and 3rd line soft tissue sarcoma subtypes.
- Initiate the Phase 2/3 program in presurgical breast cancer with the start of INVINCIBLE-4, a Phase 2 randomized controlled trial testing two doses of INT230-6 prior to SOC (immune-chemotherapy) compared to the SOC alone.
- The endpoint for this portion of the study is the change in the pathological complete response rate for the combination.
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 15 quarterly earnings reports · overlaid with Q4 2023
+0.8%
Avg return
Earnings day
-4.7%
Avg return
5 days after
+26.6%
Avg return
30 days after
40%
6 / 15 earnings
Positive
+17.3%
Q4 2023
Best reaction
-6.2%
Q3 2024
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2026 | +4.4% | -6.7% | -26.9% | |
| Q3 2025 | -5.8% | -16.0% | -8.2% | |
| Q2 2025 | +7.2% | +15.1% | +11.9% | |
| Q1 2025 | -5.8% | -22.6% | -38.6% | |
| Q4 2024 | +0.5% | -18.3% | -18.7% | |
| Q3 2024 | -6.2% | -7.4% | -39.2% | |
| Q2 2024 | -4.2% | -11.1% | -17.1% | |
| Q1 2024 | +6.7% | +17.9% | +27.5% | |
| Q1 2023 | +6.7% | +17.9% | +27.5% | |
| Q4 2023 | +17.3% | +22.0% | +12.0% | |
| Q3 2023 | -4.0% | -22.8% | +263.2% | |
| Q3 2022 | -4.0% | -22.8% | +263.2% | |
| Q4 2022 | -0.4% | -5.1% | -19.0% | |
| Q2 2023 | -0.4% | -5.1% | -19.0% | |
| Q2 2022 | -0.4% | -5.1% | -19.0% | |
| Q1 2022 | — | — | — | |
| Q4 2021 | — | — | — | |
| Q3 2021 | — | — | — | |
| Q2 2021 | — | — | — | |
| Q1 2021 | — | — | — | |
| Q4 2020 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro